Katharina Wittfeld1,2, Mekala R Raman3,4, Sarah C Conner5, Asra Aslam6, Alexander Teumer7,8,9, Matthias Nauck8,10, Norbert Hosten11, Mohamad Habes12,13,14, Charles DeCarli15, Ramachandran S Vasan4,16,17, Alexa S Beiser3,4,5, Jayandra J Himali3,4,5,12, Sudha Seshadri3,4,12, Hans J Grabe1,2, Claudia L Satizabal3,4,12. 1. German Center for Neurodegenerative Diseases (DZNE), Site Rostock/Greifswald, Germany. 2. Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany. 3. Department of Neurology, Boston University School of Medicine, Boston, MA, USA. 4. Framingham Heart Study, Framingham, MA, USA. 5. Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA. 6. Long School of Medicine, UT Health San Antonio, San Antonio, TX, USA. 7. Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany. 8. DZHK (German Center for Cardiovascular Research), Partner Site Greifswald, Greifswald, Germany. 9. Department of Population Medicine and Lifestyle Diseases Prevention, Medical University of Bialystok, Bialystok, Poland. 10. Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany. 11. Institute of Diagnostic Radiology and Neuroradiology, University Medicine Greifswald, Greifswald, Germany. 12. Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, UT Health San Antonio, San Antonio, TX, USA. 13. Department of Radiology, Center for Biomedical Image Computing and Analytics, University of Pennsylvania, Philadelphia, PA, USA. 14. Department of Neurology, Penn Memory Center, University of Pennsylvania, Philadelphia, PA, USA. 15. Department of Neurology, University of California, Davis School of Medicine, Sacramento, CA, USA. 16. Department of Medicine, Boston University School of Medicine, Boston, MA, USA. 17. Department of Epidemiology, Boston University School of Public Health, Boston MA, USA.
Abstract
BACKGROUND: Insulin-like growth factor 1 (IGF-1) signaling has been implicated in Alzheimer's disease pathogenesis, and further evidence suggests inflammation can be a moderator of this association. However, most research to date has been conducted on older adults. OBJECTIVE: To investigate the association of serum IGF-1 and IGF binding protein 3 (IGFBP-3) concentrations with MRI markers of Alzheimer's disease in predominantly middle-aged adults, and further assess moderation by chronic inflammation. METHODS: We included participants from the Framingham Heart Study (n = 1,852, mean age 46±8, 46% men) and the Study of Health in Pomerania (n = 674, mean age 50±13, 42% men) with available serum IGF-1, IFGBP-3, as well as brain MRI. IGF-1 and IFGBP-3 were related to MRI outcomes (i.e., total brain, cortical gray matter, white matter, white matter hyperintensities (WMH), and hippocampal volumes) using multivariable regression models adjusting for potential confounders. Subgroup analyses by C-reactive protein (CRP) concentrations were also performed. Cohort-specific summary statistics were meta-analyzed using random-effects models and corrected for multiple comparisons. RESULTS: Meta-analysis results revealed that higher IGF-1 concentrations were associated with lower WMH (estimate [β] [95% CI], -0.05 [-0.09, -0.02], p = 0.006) and larger hippocampal volumes (0.07 [0.02, 0.12], p = 0.01), independent of vascular risk factors. These associations occurred predominantly in individuals with CRP concentrations < 75th percentile. We did not observe associations between IGFBP-3 and MRI outcomes. CONCLUSION: Our findings suggest that IGF-1-related signaling may be implicated in brain health as early as midlife.
BACKGROUND: Insulin-like growth factor 1 (IGF-1) signaling has been implicated in Alzheimer's disease pathogenesis, and further evidence suggests inflammation can be a moderator of this association. However, most research to date has been conducted on older adults. OBJECTIVE: To investigate the association of serum IGF-1 and IGF binding protein 3 (IGFBP-3) concentrations with MRI markers of Alzheimer's disease in predominantly middle-aged adults, and further assess moderation by chronic inflammation. METHODS: We included participants from the Framingham Heart Study (n = 1,852, mean age 46±8, 46% men) and the Study of Health in Pomerania (n = 674, mean age 50±13, 42% men) with available serum IGF-1, IFGBP-3, as well as brain MRI. IGF-1 and IFGBP-3 were related to MRI outcomes (i.e., total brain, cortical gray matter, white matter, white matter hyperintensities (WMH), and hippocampal volumes) using multivariable regression models adjusting for potential confounders. Subgroup analyses by C-reactive protein (CRP) concentrations were also performed. Cohort-specific summary statistics were meta-analyzed using random-effects models and corrected for multiple comparisons. RESULTS: Meta-analysis results revealed that higher IGF-1 concentrations were associated with lower WMH (estimate [β] [95% CI], -0.05 [-0.09, -0.02], p = 0.006) and larger hippocampal volumes (0.07 [0.02, 0.12], p = 0.01), independent of vascular risk factors. These associations occurred predominantly in individuals with CRP concentrations < 75th percentile. We did not observe associations between IGFBP-3 and MRI outcomes. CONCLUSION: Our findings suggest that IGF-1-related signaling may be implicated in brain health as early as midlife.
Authors: Greta Lee Splansky; Diane Corey; Qiong Yang; Larry D Atwood; L Adrienne Cupples; Emelia J Benjamin; Ralph B D'Agostino; Caroline S Fox; Martin G Larson; Joanne M Murabito; Christopher J O'Donnell; Ramachandran S Vasan; Philip A Wolf; Daniel Levy Journal: Am J Epidemiol Date: 2007-03-19 Impact factor: 4.897
Authors: J Garcia; A Ahmadi; A Wonnacott; W Sutcliffe; K Nagga; P Soderkvist; J Marcusson Journal: Dement Geriatr Cogn Disord Date: 2006-09-15 Impact factor: 2.959
Authors: Henrike Knacke; Maik Pietzner; Kieu Trinh Do; Werner Römisch-Margl; Gabi Kastenmüller; Uwe Völker; Henry Völzke; Jan Krumsiek; Anna Artati; Henri Wallaschofski; Matthias Nauck; Karsten Suhre; Jerzy Adamski; Nele Friedrich Journal: J Clin Endocrinol Metab Date: 2016-10-06 Impact factor: 5.958
Authors: Emma R L C Vardy; Penny J Rice; Peter C W Bowie; John D Holmes; Peter J Grant; Nigel M Hooper Journal: J Alzheimers Dis Date: 2007-12 Impact factor: 4.472
Authors: Deborah Janowitz; Mohamad Habes; Jon B Toledo; Anke Hannemann; Stefan Frenzel; Jan Terock; Christos Davatzikos; Wolfgang Hoffmann; Hans Jörgen Grabe Journal: Brain Imaging Behav Date: 2020-08 Impact factor: 3.224
Authors: Karin M E Andersson; Caroline Wasén; Lina Juzokaite; Lovisa Leifsdottir; Malin C Erlandsson; Sofia T Silfverswärd; Anna Stokowska; Marcela Pekna; Milos Pekny; Kjell Olmarker; Rolf A Heckemann; Marie Kalm; Maria I Bokarewa Journal: Proc Natl Acad Sci U S A Date: 2018-12-03 Impact factor: 11.205